Neurofilament in CSF—A biomarker of disease activity and long-term prognosis in multiple sclerosis

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study

(2016) Axel Petzold et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study

(2016) Axel Petzold et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

(2014) Alessandro Trentini et al.   JOURNAL OF NEUROLOGY

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal